The BALANCE trial results presented at the ASTRO 2025 meeting demonstrate the PAM50 molecular signature's effectiveness in identifying men with recurrent prostate cancer who benefit from hormone therapy combined with salvage radiation. Involving 295 participants, the study revealed that those with luminal B tumors showed a significant improvement in biochemical failure-free survival when treated with apalutamide compared to the placebo group. These findings underline the importance of integrating biomarkers like PAM50 into clinical practice for enhanced precision in oncological diagnostics.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.